Tag Archives: Gilead Sciences (GILD)

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD) Wins FDA Approval for Hepatitis C Drug That Costs More Than $1000 a Pill

Gilead Sciences, Inc. (GILD) Wins FDA Approval for Hepatitis C Drug That Costs More Than $1000 a Pill

Gilead Sciences, Inc. (NASDAQ:GILD) has finally secured U.S. Food and Drug Administration’s approval for its Hepatitis C drug. The once-a-day pill is however coming into the market even pricier than Solvadi, which costs $1000 a pill. The drug, which is the first only oral full treatment for the illness is said to cost $1125. The

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD), Apple Inc. (AAPL), Johnson & Johnson (JNJ): Favorite Picks Of Stillwater Investment Management

Stillwater Investment Management has a 13F portfolio value of $141.99 million, as per its recent SEC 13F filing on October 6, 2014. Its top 10 holdings amount for 47.91% of its overall portfolio. Apple Inc. (NASDAQ:AAPL), Gilead Sciences, Inc. (NASDAQ:GILD), Johnson & Johnson (NYSE:JNJ) are among the top stock holdings of Stillwater Investment Management. With

AbbVie Inc (ABBV)

AbbVie Inc (ABBV), Gilead Sciences, Inc. (GILD), Ecolab Inc. (ECL): Top 3 Stock Holdings of Swarthmore Group Inc CIK

Swarthmore Group Inc CIK has 13F portfolio worths $1.07 billion, as per its recent SEC 13F filing, and its top 10 holdings account for 46.87% of its net portfolio. Ms. Paula Mandle is the CEO of the Swarthmore Group, Inc and it was founded in 1991 James E. Nevels. AbbVie Inc (NYSE:ABBV), Gilead Sciences, Inc. (NASDAQ:GILD),

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD) Says Pancreatic Cancer Treatment, Simtuzumab, Failed to Meet Trial Goals in Phase II

Gilead Sciences, Inc. (NASDAQ:GILD), a biotech company, has announced unsatisfactory results from a study that was meant to establish the efficacy of simtuzumab in Pancreatic Cancer Treatment. The study, which was at phase II, involved adding 200 or 700 milligrams of simtuzumab to gemcitabine in a bid to establish whether that would substantially improve progression-free

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD) Strikes Deal for Cheaper Hepatitis C Drugs for Developing Countries

Developing countries will soon receive cheaper hepatitis C drugs; thanks to a deal Gilead Sciences, Inc. (NASDAQ:GILD) signed with Indian companies to develop generic versions of the drug. The deal allows the companies to make sofusbivir, which is sold under the name Sovaldi, and sell it in 91 specified countries. The drug costs $1,000 a

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD) Raises the New Hepatitis C Drug Price to Above $84,000

Gilead Sciences, Inc. (NASDAQ:GILD) is already being attacked for the unbelievable price tag for the next generation oral hepatitis C drug, which is expected to be released next month. Currently, full treatment of the hepatitis C virus costs $95,000; a subscription that includes Sovaldi, ribavirin and interferon. The next generation drug to be released is

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD) to Offer Low-cost Versions of Hepatitis C in lower economies

In a scintillating string of events, Gilead Sciences, Inc (NASDAQ:GILD) is in talks with generic drug makers to offer a low-cost versions of its premium $84,000 Hepatitis C treatment, Sovaldi, in developing countries including India, Pakistan, Indonesia, and nearly 80 countries. Gilead Sciences, Inc (NASDAQ:GILD) offers Sovaldi treatment at a cost of $84,000 in the

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD), Intel Corporation (INTC), Kinder Morgan Inc (KMI), Monster Beverage Corp (MNST): Jim Cramer’s Most Favorite Stocks in August

This has been the best August for the stock market in the past 14 years and it is time to consider the stocks that caught Jim Cramer’s eyes. Jim Cramer recommended each of these stocks at least thrice throughout the month including Gilead Sciences, Inc. (NASDAQ:GILD), Intel Corporation (NASDAQ:INTC), Kinder Morgan Inc (NYSE:KMI), and Monster

Top